Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open-Label, Phase 1/1b Study of Escalating Doses of RO5503781 Administered Orally as 1) a Single Agent, 2) In Combination With Cytarabine, or 3) With Cytarabine and Anthracycline and 4) Assessing PK and Safety of New Optimized Formulation of RO5503781 With Cytarabine in Patients With Acute Myelogenous Leukemia (AML)

Trial Profile

A Multi-Center, Open-Label, Phase 1/1b Study of Escalating Doses of RO5503781 Administered Orally as 1) a Single Agent, 2) In Combination With Cytarabine, or 3) With Cytarabine and Anthracycline and 4) Assessing PK and Safety of New Optimized Formulation of RO5503781 With Cytarabine in Patients With Acute Myelogenous Leukemia (AML)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Idasanutlin (Primary) ; Anthracyclines; Daunorubicin; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 08 Dec 2020 Results investigating the contribution of Idasanutlin exposure variability to those findings, in particular, the relationship between exposure and toxicity and efficacy in pts with AML from NCT02545283, NCT01773408, NCT01462175 and NCT03287245 presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results assessing minimal residual disease in relapsed/refractory AML patients treated with idasanutlin presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Aug 2016 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top